$CURR an innovative drug delivery company that is developing novel ways to deliver active ingredients, announced today that it strengthened its balance sheet with the receipt of $1.4 million in cash from the exercise of warrants to purchase 708,467 shares of CURE’s common stock held by certain stockholders of Chemistry Holdings, Inc. (Chemistry Holdings) at a reduced exercise price of $2.00 per share (which was 10 percent above the market price for CURE’s stock at closing). The warrant exercise is part of the completion of all earn-out arrangements and obligations related to CURE’s acquisition of Chemistry Holdings on May 14, 2019.